Skip to main content
SpringerLink
Log in

Management of Advanced Non-Small Cell Lung Cancer

The Potential Role of Gemcitabine

  • Drugs in Disease Management
  • Published:
Disease Management and Health Outcomes

Abstract

Patients with non-small cell lung cancer (NSCLC) have poor survival prospects, as most have advanced disease at diagnosis. Chemotherapy can be used to treat these patients if their performance status is good, although there are geographical differences in chemotherapy use. Combination chemotherapy regimens are usually used because monochemotherapy has only modest efficacy.

The nucleoside analogue gemcitabine is one of several new chemotherapies for NSCLC which have been developed in recent years. Like other available drugs, it has modest efficacy against NSCLC when used as monotherapy [19 to 26% objective (partial plus complete) response rate]. Gemcitabine is relatively well tolerated, causing few serious adverse effects. Myelosuppression is the most common reason for dosage adjustment during monotherapy, but such adjustments are relatively infrequent overall. Flu-like symptoms and fever, elevated hepatic enzyme levels, and nausea and vomiting are common but are usually mild or moderate. Dosage reduction and treatment withdrawal are the exception rather than the rule for patients receiving gemcitabine monotherapy.

The combination of gemcitabine with cisplatin has shown good antitumour efficacy (26 to 54% objective response rate) in patients with NSCLC, and limited phase III data suggest that it produces objective response rates significantly higher than those of some older ‘standard’ regimens such as cisplatin plus etoposide (although survival appears similar). Gemcitabine plus cisplatin produces grade 3 or 4 myelosuppression in many patients, but this has generally proved manageable and has not limited clinical use. Data from phase III comparisons of gemcitabine plus cisplatin with currently recommended combination regimens (which include some of the other newer agents for NSCLC, e.g. paclitaxel or vinorelbine) are not yet available.

Conclusions

Gemcitabine is now a well established chemotherapy for NSCLC which is approved for use in many countries, but its precise role in an indication with numerous treatment options and combination regimens is clearly still evolving. Gemcitabine-containing combination regimens are being tested in a number of phase III trials and data from these studies are awaited with interest. The relatively benign tolerability profile of gemcitabine may prove useful in elderly patients (limited available data from this group are favourable) or patients with coexisting disease states, since tolerance of toxicities is likely to be lower in these groups than in other patients. Non-cisplatin-based combination regimens are currently being investigated in an attempt to further improve the tolerability of chemotherapy for NSCLC, and gemcitabine is likely to play a significant role in this respect.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Noble S, Goa KL. Gemcitabine: a review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer. Drugs 1997 Sep; 54: 447–72

    Article  PubMed  CAS  Google Scholar 

  2. Kelly P, Clancy L. Is the use of chemotherapy justified in non-small-cell lung cancer? Drugs Aging 1994 Jan; 4: 1–8

    Article  PubMed  CAS  Google Scholar 

  3. Haskell CM, Holmes EC. Non-small cell lung cancer. Dis Mon 1988 Feb; 34: 53–108

    Article  PubMed  CAS  Google Scholar 

  4. Vainio H, Heseltine E. Tobacco and cancer. Cancer Res 1986 Jan; 46: 444–7

    Google Scholar 

  5. Loeb LA, Ernster VL, Warner KE, et al. Smoking and lung cancer: an overview. Cancer Res 1984 Dec; 44: 5940–58

    PubMed  CAS  Google Scholar 

  6. Fraumeni Jr JF, Blot WJ. Lung and pleura. In: Schottenfeld D, Fraumeni Jr J, editors. Cancer epidemiology and prevention. Philadelphia: W.B. Saunders, 1982: 564–82

    Google Scholar 

  7. Smit EF, Groen HJ, Splinter TA, et al. New prognostic factors in resectable non-small cell lung cancer. Thorax 1996 Jun; 51: 638–46

    Article  PubMed  CAS  Google Scholar 

  8. American Cancer Society. Lung cancer 1998 facts & figures [online]. American Cancer Society; 1999. Available from: URL: http://www.cancer.org/statistics/cff98/selectedcancers.html [Accessed 1999 Jan 14]

  9. Parker SL, Tong T, Bolden S, et al. Cancer Statistics, 1996. CA Cancer J Clin 1996; 65: 5–27

    Article  Google Scholar 

  10. Travis WD, Lubin J, Ries L, et al. United States lung carcinoma incidence trends: declining for most histologic types among males, increasing among females. Cancer 1996 Jun 15; 77: 2464–70

    Article  PubMed  CAS  Google Scholar 

  11. Desch CE, Hillner BE, Smith TJ. Economic considerations in the care of lung cancer patients. Curr Opin Oncol 1996 Mar; 8: 126–32

    Article  PubMed  CAS  Google Scholar 

  12. American Society of Clinical Oncology. Clinical practice guidelines for the treatment of unresectable non—small-cell lung cancer. J Clin Oncol 1997 Aug; 15: 2996–3018

    Google Scholar 

  13. National Cancer Institute. Non-small cell lung cancer for physicians. In: PDQ information for health care professionals [online]. National Cancer Institute; 1998. Available from: http://www.cancernet.nci.nih.gov/clinpdq/soa/Non-smallcelllungcancerPhysician.html [Accessed 1998 Sep 23]

  14. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997; 111: 1710–7

    Article  PubMed  CAS  Google Scholar 

  15. Mountain CF. A new international staging system for lung cancer. Chest 1986 Apr; 89(4) Suppl.: 225S–33S

    Article  PubMed  CAS  Google Scholar 

  16. Billingham LJ, Cullen MH, Woods J, et al. Mitomycin, ifosfamide and cisplatin (MIC) in non-small cell lung cancer (NSCLC): 3. Results of a randomised trial evaluting palliation and quality of life [abstract no. 26]. Lung Cancer 1997; 18 Suppl.: 9–10

    Article  Google Scholar 

  17. Helsing M, Bergman B, Thaning L, et al. Quality of life and survival in patients with advanced non-small cell lung cancer receiving suppportive care plus chemotherapy with carboplatin and etoposide or supportive care only: a multicentre randomised phase III trial. Eur J Cancer 1998; 34(7): 1036–44

    Article  PubMed  CAS  Google Scholar 

  18. Clerici M, Frontini L, Ianniello GP, et al. Vinorelbine plus best supportive care (BSC) vs BSC in the treatment of advanced non small cell lung cancer (NSCLC) elderly patients (pts): results of a phase III randomized trial [abstract no. 064]. Ann Oncol 1998; 62 Suppl. 3: 62

    Google Scholar 

  19. Dillman RO, Herndon JH, Seagren SL, et al. Improved survival in stage ITI non-small-cell lung cancer: seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 Trial. J Natl Cancer Inst 1996 Sep 4; 88(17): 1210–5

    Article  PubMed  CAS  Google Scholar 

  20. Pritchard RS, Anthony SP. Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer: a metaanalysis. Ann Intern Med 1996 Nov 1; 125: 723–9

    PubMed  CAS  Google Scholar 

  21. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non—small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995; 311: 899–909

    Article  Google Scholar 

  22. Sause WT, Scott C, Taylor S, et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 1995 Feb 1; 87: 198–205

    Article  PubMed  CAS  Google Scholar 

  23. Schaake-Koning C, van den Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N Engl J Med 1992 Feb 20; 326(9): 524–30

    Article  PubMed  CAS  Google Scholar 

  24. Le Chevalier T, Arriagada R, Quoix E, et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in non-resectable non-small cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst 1991 Mar 20; 83(6): 417–23

    Article  PubMed  Google Scholar 

  25. Dillman RO, Seagren SL, Propert KJ, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 1990 Oct 4; 323(14): 940–5

    Article  PubMed  CAS  Google Scholar 

  26. Roseli R, Gomez-Codina J, Camps C, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small cell lung cancer. N Engl J Med 1994; 330: 153–8

    Article  Google Scholar 

  27. Roth JA, Fossella F, Komaki R, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small cell lung cancer. J Natl Cancer Inst 1994; 86: 650–1

    Article  Google Scholar 

  28. Marino P, Pampallona S, Preatoni A, et al. Chemotherapy vs supportive care in advanced non-small cell lung cancer: results of a meta-analysis of the literature. Chest 1994 Sep; 106(3): 861–5

    Article  PubMed  CAS  Google Scholar 

  29. Souquet PJ, Chauvin F, Boissel JP, et al. Polychemotherapy in advanced non small cell lung cancer: a meta-analysis. Lancet 1993 Jul 3; 342: 19–21

    Article  PubMed  CAS  Google Scholar 

  30. Grilli R, Oxman AD, Julian JA. Chemotherapy for advanced non—small cell lung cancer: how much benefit is enough? J Clin Oncol 1993 Oct; 11(10): 1866–72

    PubMed  CAS  Google Scholar 

  31. Giaccone G, Splinter TAW, Debruyne C, et al. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non—small-cell lung cancer. J Clin Oncol 1998 Jun; 16: 2133–41

    PubMed  CAS  Google Scholar 

  32. Le Chevalier T, Brisgand D, Douillard J-Y, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non—small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 1994 Feb; 12(2): 360–7

    PubMed  Google Scholar 

  33. Belani CP. Paclitaxel/carboplatin in the treatment of non-small-cell lung cancer. Oncology 1998 Jan; 12 Suppl. 2: 74–9

    PubMed  CAS  Google Scholar 

  34. Eli Lilly and Company. Gemzar® (gemcitabine HCl) for injection. US prescribing information. Indianapolis: Eli Lilly and Company, 1999

    Google Scholar 

  35. Aapro MS, Martin C, Hatty S. Gemcitabine — a safety review. Anticancer Drugs 1998; 9: 191–201

    Article  PubMed  CAS  Google Scholar 

  36. Abratt RP, Bezwoda WR, Goedhals L, et al. Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small cell lung cancer. J Clin Oncol 1997 Feb; 15(2): 744–9

    PubMed  CAS  Google Scholar 

  37. Antón A, Artal A, Carrata A, et al. Gemcitabine plus cisplatin in advanced NSCLC: final phase II results [abstract no. 1656]. Thirty-Third Annual Meeting, American Society of Clinical Oncology; 1997 May 17–20; Denver, 461a

    Google Scholar 

  38. Crinò L, Scaglioni G, Marangolo M, et al. Cisplatin-gemcitabine combination in advanced non-small cell lung cancer: a phase II study. J Clin Oncol 1997; 15: 297–303

    PubMed  Google Scholar 

  39. González-Barón M, Ordonez A, Gracia M, et al. Gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC): results from a phase II study [abstract no. 1687]. Thirty-Third Annual Meeting, American Society of Clinical Oncology; 1997 May 17–20; Denver, 469a

    Google Scholar 

  40. Sandler AB, Ansari R, McClean J, et al. A Hoosier Oncology Group phase II study of gemcitabine plus cisplatin in non-small cell lung cancer (NSCLC) [abstract]. Proc Am Soc Clin Oncol 1995 Mar; 14: 357

    Google Scholar 

  41. Shepherd FA, Cormier Y, Burkes R, et al. Phase II trial of gemcitabine and weekly cisplatin for advanced non-small cell lung cancer. Semin Oncol 1997 Jun; 24(3) Suppl. 8: S27–30

    Google Scholar 

  42. Steward WP, Dunlop DJ, Cameron C, et al. Phase I/II study of cisplatin in combination with gemcitabine in non-small cell lung cancer (NSCLC) [abstract]. Proc Am Soc Clin Oncol 1995 Mar; 14: 351

    Google Scholar 

  43. Eli Lilly and Company. Phase 3 trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small cell lung cancer (Clinical Study Synopsis — Study B9E-MC-JHEX). Eli Lilly and Company (Indianapolis), 1999. (Data on file)

  44. Cardenal F, López-Cabrerizo MP, Antón A, et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non—small-cell lung cancer. J Clin Oncol 1999 Jan; 17(1): 12–8

    PubMed  CAS  Google Scholar 

  45. A randomized phase III study of gemcitabine/cisplatin versus mitomycin/ifosfamide/cisplatin in advanced non-small cell lung cancer. Indianapolis: Eli Lilly and Company, 1999. (Data on file)

  46. Abratt RP, Bezwoda WR, Falkson G, et al. Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. J Clin Oncol 1994 Aug; 12: 1535–40

    PubMed  CAS  Google Scholar 

  47. Anderson H, Lund B, Bach F, et al. Single-agent activity of weekly gemcitabine in advanced non—small-cell lung cancer: a phase II study. J Clin Oncol 1994 Sep; 12: 1821–6

    PubMed  CAS  Google Scholar 

  48. Begbie SD, Hui R, Levi JA, et al. Initial experience with gemcitabine for non-small cell lung cancer in Australia [abstract]. Proc Am Soc Clin Oncol 1995 Mar; 14: 378

    Google Scholar 

  49. Crinò L, Mosconi AM, Scagliotti GV, et al. Gemcitabine as second-line treatment for relapsing or refractory advanced non-small cell lung cancer: a phase II trial. Semin Oncol 1998 Aug; 25(4) Suppl. 9: 23–6

    PubMed  Google Scholar 

  50. Fossella FV, Lippman SM, Shin DM, et al. Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer. J Clin Oncol 1997 Jan; 15(1): 310–6

    PubMed  CAS  Google Scholar 

  51. Takada M, Negoro S-i, Kudo S, et al. Activity of gemcitabine in non-small-cell lung cancer: results of the Japan gemcitabine group (A) phase II study. Cancer Chemother Pharmacol 1998 Feb; 41: 217–22

    Article  PubMed  CAS  Google Scholar 

  52. Gatzemeier U, Shepherd FA, Le Chevalier T, et al. Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study. Eur J Cancer A 1996 Feb; 32A: 243–8

    Article  PubMed  CAS  Google Scholar 

  53. Lund B, Ryberg M, Petersen PM, et al. Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) given as a twice weekly schedule to previously untreated patients with non-small cell lung cancer. Ann Oncol 1994 Nov; 5: 852–3

    PubMed  CAS  Google Scholar 

  54. Malayeri R, Ulsperger E, Baumgartner G, et al. Gemcitabine in the treatment of non-small-cell lung cancer [abstract no. 460P]. Ann Oncol 1996; 7 Suppl. 5: 97

    Google Scholar 

  55. Yokoyama A, Nakai Y, Yoneda S, et al. Activity of gemcitabine in the treatment of patients with non-small cell lung cancer: a multicenter phase II study. Anticancer Drugs 1997 Jul; 8: 574–81

    Article  PubMed  CAS  Google Scholar 

  56. Halme M, Jekunen A, Tamminen K, et al. Phase II study of weekly gemcitabine in advanced non-small cell lung cancer. Respir Med 1997 Aug; 91: 423–6

    Article  PubMed  CAS  Google Scholar 

  57. Perng R-P, Chen Y-M, Ming-Liu J, et al. Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study. J Clin Oncol 1997 May; 15(5): 2097–102

    PubMed  CAS  Google Scholar 

  58. Manegold C, Bergman B, Chemaissani A, et al. Single-agent gemcitabine versus cisplatin-etoposide: early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer. Ann Oncol 1997 Jun; 8: 525–9

    Article  PubMed  CAS  Google Scholar 

  59. Anderson H, Hopwood P, Stephens R, et al. Phase III study of gemcitabine (Gemzar™) versus best supportive care in advanced/metastatic non-small cell lung cancer. Presented at 8th World Conference on Lung Cancer; 1997 Aug 10–15, Dublin

  60. Bianco V, Gianni W, Pietropaolo M, et al. Gemcitabine in aged NSCLC patients: preliminary results [abstract no. 082]. Ann Oncol 1998; 9 Suppl. 3: 67

    Google Scholar 

  61. Lippe P, Silva RR, Giuliodori L, et al. Advanced non-small cell lung cancer (ANSCLC) in the elderly: effective and well tolerated weekly gemcitabine (GEM) and cisplatin (CDDP) regimen [abstract no. 069]. Ann Oncol 1998; 9 Suppl. 3: 64

    Google Scholar 

  62. Tibaldi C, Ricci S, Bonifazi F, et al. Preliminary results of a multicentre phase II study with gemcitabine monotherapy in the elderly patients with advanced non small cell lung cancer (NSCLC) [abstract no. 143]. Ann Oncol 1998; 9 Suppl. 3: 83

    Google Scholar 

  63. Ardizzoni A, Tixi L, Rosso R, et al. NSCLC in the elderly, gemcitabine: a step beyond [abstract no. 005]. Ann Oncol 1998; 9 Suppl. 3: 11

    Google Scholar 

  64. Evans WK. Cost-effectiveness of gemcitabine in stage IV non-small cell lung cancer: an estimate using the population health model lung cancer module. Semin Oncol 1997 Apr; 24 Suppl. 7: 56–63

    Google Scholar 

  65. Copley-Merriman C, Martin C, Johnson N, et al. Economic value of gemcitabine in non-small cell lung cancer. Semin Oncol 1996 Oct; 23 Suppl. 10: 90–8

    PubMed  CAS  Google Scholar 

  66. Copley-Merriman C, Corral J, King K, et al. Economic value of gemcitabine compared to cisplatin and etoposide in non-small cell lung cancer. Lung Cancer 1996 Feb; 14: 45–61

    Article  PubMed  CAS  Google Scholar 

  67. Koch P, Johnson N, van Schaik J, et al. Gemcitabine: clinical and economic impact in inoperable non-small cell lung cancer. Anticancer Drugs 1995 Dec; 6 Suppl. 6: 49–54

    Article  PubMed  CAS  Google Scholar 

  68. Ragnarson Tenvall G, Fernberg J-O, Grupper M, et al. Chemotherapy treatment in stage IIIB and IV NSCLC — a health economic evaluation of gemcitabine vs standard treatment [abstract no. 467P]. Ann Oncol 1995; 7 Suppl. 5

  69. Crott R, Gilis P, Martin C. Economic evaluation of the use of gemcitabine as single agent in NSCLC in Belgium. Presented at 6th International Congress on Anti-Cancer Treatment; 1996 Feb 4–9; Paris

  70. Rosell R, Sacristán JA, Duthie T, et al. Cost-effectiveness of gemcitabine (Gemzar™) plus cisplatin versus etoposide plus cisplatin for advanced non small cell lung cancer (NSCLC) in Spain [abstract no. 445P]. Ann Oncol 1998; 9 Suppl. 4: 92–3

    Google Scholar 

  71. Palmer AJ, Brandt A. The cost-effectiveness of four cisplatin-containing chemotherapy regimens in the treatment of stages ITI B and IV non-small cell lung cancer: an Italian perspective. Monaldi Arch Chest Dis 1996; 51(4): 279–88

    PubMed  CAS  Google Scholar 

  72. Androulakis N, Kouroussis C, Kakolyris S, et al. Salvage treatment with paclitaxel and gemcitabine for patients with non-small-cell lung cancer after cisplatin- or docetaxel-based chemotherapy: a multicentre phase II study. Ann Oncol 1998 Oct; 9(10): 1127–30

    Article  PubMed  CAS  Google Scholar 

  73. Papadakis E, Kourousis C, Kakolyrts S, et al. Second line treatment of advanced non-small cell lung cancer after cisplatin-based chemotherapy with paclitaxel and gemcitabine [abstract no. 163]. Lung Cancer 1997; 18 Suppl.: 44

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Adis International Limited, Private Bag 65901, Mairangi Bay, Auckland 10, New Zealand

    Stuart Noble & Diana Faulds

Authors
  1. Stuart Noble
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Diana Faulds
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stuart Noble.

Additional information

Various sections of the manuscript reviewed by: R. Abratt, Department of Radiation Oncology, University of Cape Town, Groote Schuur Hospital, Cape Town, South Africa; C.P. Belani, Lung Cancer Program, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, USA; S. Clarke, Department of Medical Oncology, Sydney Cancer Centre, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia; W.K. Evans, Ottawa Regional Cancer Centre, Stittsville, Ontario, Canada; G. Giaccone, Division of Oncology, University Hospital Vrije Universiteit, Amsterdam, The Netherlands; D. Gilligan, Department of Clinical Oncology, Addenbrooke’s NHS Trust, Cambridge, England; K.M.W. Pisters, Thoracic Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; P.E. Postmus, Department of Pulmonary Medicine, Amsterdam Free University, Amsterdam, The Netherlands.

Data Selection

Sources: Medical literature published in any language since 1966 on gemcitabine, identified using AdisBase (a proprietary database of Adis International, Auckland, New Zealand), Medline and EMBASE. Additional references were identified from the reference lists of published articles. Bibliographical information, including contributory unpublished data, was also requested from the company developing the drug.

Search strategy: AdisBase search terms were ‘gemcitabine’, ‘non—small cell lung cancer’. Medline and EMBASE search terms were ‘gemcitabine’ and ‘non—small cell lung cancer’. Searches were last updated 28 January 1999.

Selection: Studies in patients with advanced non—small cell lung cancer who received gemcitabine. Inclusion of studies was based mainly on the methods section of the trials. When available, large, well controlled trials with appropriate statistical methodology were preferred. Relevant pharmacodynamic and pharmacokinetic data are also included.

Index terms: gemcitabine, non—small cell lung cancer, chemotherapy, oncology, pharmacokinetics, pharmacodynamics, therapeutic use, tolerability.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Noble, S., Faulds, D. Management of Advanced Non-Small Cell Lung Cancer. Dis-Manage-Health-Outcomes 5, 167–179 (1999). https://doi.org/10.2165/00115677-199905030-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00115677-199905030-00005

Keywords

Search

Navigation